

Mandated Substance Use Disorder Treatment in Qatar: An Innovative Model of Care

Dr Suhair Mohammed Yousuf, Dr Nirvana Swamy Kudlur Chandrappa, Dr Faycal Walid Ikhlef, Dr Wesam S Smidi and Dr Majid Ali Y. A. Al Abdulla

Mental Health Services - Hamad Medical Corporation, Doha, Qatar

doi: 10.1192/bjo.2025.10401

Aims: Qatar has struggled with substance use disorders among its population. Qatar has maintained a relative political and social stability, which has informed a dramatic restructuring of its health and social care services with emphasis on being led by international best practice and primacy of patient rights. However, the rehabilitative model for substance use, which Qatar has placed emphasis on so far, has been based upon voluntary engagement of people who use substances. This has led to lack of provision of care to a significant proportion of patients with substance use disorders in addition to system-wide disagreements around models of care.

Methods: This study employed a retrospective patient record review of 163 patients admitted to the Umm Slal Treatment and Rehabilitation Center between January 2022 and October 2023. The data were systematically analysed to evaluate the effectiveness of the innovative Recovery Journey model.

Results: The majority of patients (61.3%) were aged 20–29, with 54% unemployed or students. Methamphetamine (77.3%) and cannabis (76.1%) were the most commonly used substances. Notable comorbidities included drug-induced psychosis (29.4%) and depression (19.5%). Most patients (90%) had previous treatment encounters. The Recovery Journey model, consisting of court-mandated detoxification and stabilization, residential rehabilitation, and community based continuing care, facilitated treatment completion for 91 out of 149 patients advancing from detoxification to rehabilitation. Challenges included managing complex co-occurring disorders and aligning multidisciplinary teamworking efforts.

Conclusion: The innovative Recovery Journey model at the Umm Slal Treatment and Rehabilitation Center demonstrated promising results in treating individuals with substance use disorders. While initial outcomes are encouraging, challenges related to stakeholder engagement, treatment adherence, and post-discharge care remain. This model emphasizes the importance of balancing directed care with patient autonomy and may serve as a framework for similar initiatives in the region. Further research into and adaptation of cultural contexts are essential for optimizing treatment outcomes.

Safer Prescribing in Behavioural and Psychological Symptoms of Dementia (BPSD): Reducing Anticholinergic Burden

Dr Jessica May¹, Dr Nurul Ain Mohd Nizam¹, Dr Elisabeth Henrika Bonor¹, Ms Louisa Marchant-Rutherford¹ and Dr Scott Cherry¹

¹Sussex Partnership NHS Foundation Trust, Brighton, United Kingdom and ²University Hospitals Sussex NHS Foundation Trust, Brighton, United Kingdom

doi: 10.1192/bjo.2025.10402

Aims: NICE guidelines (NG97) emphasize the importance of assessing the anticholinergic burden of medications in older adults. Anticholinergic side effects of medications can worsen constipation, urinary retention, sedation and confusion, exacerbating cognition, falls and BPSD risks.

Medichec, a free online tool, measures medication effects on cognition and evaluates the cumulative impact. The tool provides an Anticholinergic Effect on Cognition (AEC) score for each medication, ranging from 0-3. The greater the score, the greater the need to evaluate its benefits versus risks.

This project aimed to evaluate the effectiveness of integrating the AEC score into multidisciplinary management of dementia inpatients.

Methods: In a 10-bed specialist dementia ward, AEC score was calculated weekly over four weeks for each patient using Medichec. This included 15 inpatients over 4 weeks. Medications contributing to AEC score were recorded and reviewed during the weekly ward multidisciplinary meetings. Individual plans were then made to reduce, hold, or stop medication where appropriate.

Results: Total AEC scores were between 1–7 for each patient, scoring primarily for psychotropic medications. The weekly percentage of patients with total AEC scores over 3 on the ward ranged between 10-37.5%. The overall trend in percentage of patients with a score over 3 showed a reduction from 37.5% at baseline to 20% at week 4.

There were 10 occasions where patients had an AEC score of 3 +; on 90% of these occasions there was a documented multidisciplinary care plan and these 10 occasions represented 5 individual patients. Of these 5 patients, medications were adjusted for 2 patients, continued for 2 patients and not discussed for 1 patient.

The mean AEC score varied between 1.5-2.13; there was no reduction from baseline (1.89) to week 4 (1.9) however the average in week 4 was skewed by an outlying individual result of 7.

Conclusion: The weekly data collected in this audit supports a culture of avoiding medications with high anticholinergic burden for physical health reasons e.g. antimuscarinics for incontinence. Additionally, medications for insomnia, like 'Z-drugs', are not routinely prescribed. This helps lower the risks of side effects and aligns with NICE (NG97) guidelines for managing medications which can adversely affect cognition.

Medications with an individual anticholinergic score of 2+ or patients with a total score of 3+ on Medichec should trigger a review as this can have a clinically significant impact on individual patients.

Implementing a Clinician-Built High-Dose Antipsychotic Therapy (HDAT) Calculator and Tracker: A Quality Improvement Project to Optimise HDAT Monitoring and Safe Prescribing

Dr Nurul Ain Mohd Nizam, Dr Isabelle Tighe, Ms Claire Butler and Dr Paul Harris

Sussex Partnership NHS Foundation Trust, Brighton, United Kingdom

doi: 10.1192/bjo.2025.10403

Aims: High-dose antipsychotic therapy (HDAT) carries an increased risk of adverse effects, including metabolic syndrome

Abstracts were reviewed by the RCPsych Academic Faculty rather than by the standard *BJPsych Open* peer review process and should not be quoted as peer-reviewed by *BJPsych Open* in any subsequent publication.

Abstracts were reviewed by the RCPsych Academic Faculty rather than by the standard *BJPsych Open* peer review process and should not be quoted as peer-reviewed by *BJPsych Open* in any subsequent publication.

and extrapyramidal side effects, requiring regular monitoring. However, adherence remains inconsistent due to challenges in patient attendance, staff awareness, and varying monitoring intervals. This quality improvement project aimed to determine the prevalence of HDAT use in an assertive outreach team, assess adherence to the local trust HDAT monitoring guidelines, and implement a clinician-built HDAT Calculator and Tracker to improve monitoring efficiency.

Methods: In the absence of an electronic prescribing system, monitoring was routinely done manually. Therefore, clinicians created an HDAT Calculator and Tracker using Microsoft Excel, based on local trust HDAT monitoring guidelines and the Prescribing Observatory for Mental Health (POMH) Ready Reckoner Version 11, to automatically calculate and identify patients on HDAT, flag upcoming and overdue assessments, and facilitate monitoring. Data collected included the dates and results of the most recent electrocardiogram (ECG), blood tests, quantitative antipsychotic side effect assessments, and weight.

Results: Of 105 patients reviewed, 11 (10%) were identified as receiving HDAT at the time of data collection. 5 of the 11 patients on HDAT were in an inpatient setting. ECG and blood test compliance were both 91%, with reasons for missing parameters documented in all but one instance. 2 of 11 patients were due for their annual weight assessment. Notably, gaps were identified in the documentation of quantitative antipsychotic side effect assessments, with 3 of 11 patients lacking a recorded assessment and 4 of 8 overdue for their annual review.

Clinicians identified a significant challenge in monitoring patients after HDAT initiation due to varying intervals between required assessments (e.g. 3–4 days, 1 month and 3 months post HDAT initiation) and the complexity of ensuring timely follow-up. The HDAT Calculator and Tracker offered a systematic, sustainable solution, enabling clinicians to recognise upcoming assessments and plan timely interventions. Overall, feedback highlighted reduced administrative workload and increased confidence in ensuring continuity of care and safe prescribing.

Conclusion: This project highlights the importance of structured, ongoing monitoring in psychiatric practice and presents a model for improving safe prescribing in high-risk populations. Future steps include iterative updates to the tool as new knowledge emerges, increasing HDAT monitoring awareness within the multi-disciplinary team (particularly around the adverse effects of HDAT), joining up care with local physical health clinics, embedding the tool into routine clinical practice and integrating it with electronic patient records and prescribing systems currently under development.

Working Diagnoses: A Pilot Study

Dr Zaim Mohdesham¹ and Dr Ben di Mambro²

¹Derbyshire Healthcare NHS Foundation Trust, Derby, United Kingdom and ²Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, United Kingdom

doi: 10.1192/bjo.2025.10404

Aims: Mental Health and Neurodevelopment Resource Group (MHNRG) are planned to replace Mental Health Clustering. However, they are broad diagnostic groupings which will potentially have limited benefit in relation to evaluating outcomes, health

inequalities, pathways, and interventions. In addition to mandatory completion of MHNRG, local services have the option to collect additional categorical data which led to the introduction of Working Diagnoses.

This is a pilot study to trial Working Diagnoses to test its functionality and feasibility.

Methods: The aim of the Working Diagnoses is to create an accessible form on the electronic patient record allowing assessors to select a list of up to four working diagnoses via a drop-down menu. Following consultation with clinicians from differing psychiatric specialities, a list of 53 separate working diagnoses were agreed upon which were individually mapped to their respective ICD–11 diagnostic codes and Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) to make it future proof.

The pilot was conducted within the local Crisis Resolution and Home Treatment and Primary Care Mental Health teams. A live and secure Microsoft Excel document with a list of the working diagnoses through a drop-down menu was created. Assessors consisting of both doctors of various grades and psychiatric nurses within the teams were briefed on the aims and objectives of the pilot study.

At this stage, it is not intended for the diagnostic data to flow into the Mental Health Services Data Set (MHSDS).

Results: 127 patients referred to the teams between November to December 2023 were included in the pilot study and allocated their working diagnosis; 66 received one diagnosis, 52 received two and 9 received three diagnoses and none received four.

All presentations were able to be satisfactorily described by the Working Diagnoses options. The general feedback from assessors who participated in the study reported that it was simple and easy to use despite having limited formal training.

Conclusion: We believe that mental health services require granular details of a person's presentation if we are to effectively commission, transform and manage our services. Though other options could be utilised, implementing a limited categorical diagnostic list appears to be an acceptable, effective, and efficient method of gathering the information that has been missing in mental health services locally.

The next steps will be to trial this to other services within the wider trust.

Re-Introducing the Maintenance Slot in the Maidstone KMPT ECT Suite and Enhancing the ECT Clinic's Capacity by 20%

Dr Maria Moisan, Mrs Stanimira Gogova, Ms Chiara Rubino and Dr Brett Metelerkamp

Kent and Medway NHS and Social Care Partnership Trust, Maidstone, United Kingdom

doi: 10.1192/bjo.2025.10405

Aims: Kent and Medway NHS and Social Care Partnership Trust (KMPT) had been providing fewer Electroconvulsive Therapy (ECT) treatments per capita compared with the national average. Following a reduction in patient numbers after the COVID-19 pandemic, the KMPT ECT Suite aimed to offer both initial and maintenance therapy. This required increasing the number of sessions per day to enhance clinic capacity by 20% to accommodate the reintroduction of a maintenance slot.

Abstracts were reviewed by the RCPsych Academic Faculty rather than by the standard *BJPsych Open* peer review process and should not be quoted as peer-reviewed by *BJPsych Open* in any subsequent publication.

Abstracts were reviewed by the RCPsych Academic Faculty rather than by the standard *BJPsych Open* peer review process and should not be quoted as peer-reviewed by *BJPsych Open* in any subsequent publication.